184 related articles for article (PubMed ID: 32283163)
21. Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.
Tan HW; Xu YM; Lau ATY
Rev Med Virol; 2020 Sep; 30(5):e2122. PubMed ID: 32602627
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication.
Pang X; Cui Y; Zhu Y
Acta Pharmacol Sin; 2020 Sep; 41(9):1255-1257. PubMed ID: 32581256
[No Abstract] [Full Text] [Related]
23. Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein.
Yang C; Pan X; Xu X; Cheng C; Huang Y; Li L; Jiang S; Xu W; Xiao G; Liu S
Signal Transduct Target Ther; 2020 Oct; 5(1):220. PubMed ID: 33024075
[No Abstract] [Full Text] [Related]
24. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
Sternberg A; McKee DL; Naujokat C
Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679
[TBL] [Abstract][Full Text] [Related]
25. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic.
South AM; Tomlinson L; Edmonston D; Hiremath S; Sparks MA
Nat Rev Nephrol; 2020 Jun; 16(6):305-307. PubMed ID: 32246101
[TBL] [Abstract][Full Text] [Related]
26. Drug researchers pursue new lines of attack against COVID-19.
Harrison C
Nat Biotechnol; 2020 Jun; 38(6):659-662. PubMed ID: 32417850
[No Abstract] [Full Text] [Related]
27. Purposing Saikosaponins for the treatment of COVID-19.
Bahbah EI; Negida A; Nabet MS
Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743
[No Abstract] [Full Text] [Related]
28. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
[TBL] [Abstract][Full Text] [Related]
29. Recombinant protein targeting and opsonizing spike glycoprotein for enhancing SARS-CoV-2 phagocytosis.
Khattabi L
Med Hypotheses; 2020 Oct; 143():110108. PubMed ID: 32721804
[TBL] [Abstract][Full Text] [Related]
30. A human monoclonal antibody blocking SARS-CoV-2 infection.
Wang C; Li W; Drabek D; Okba NMA; van Haperen R; Osterhaus ADME; van Kuppeveld FJM; Haagmans BL; Grosveld F; Bosch BJ
Nat Commun; 2020 May; 11(1):2251. PubMed ID: 32366817
[TBL] [Abstract][Full Text] [Related]
31. Interdiction of Protein Folding for Therapeutic Drug Development in SARS CoV-2.
Bergasa-Caceres F; Rabitz HA
J Phys Chem B; 2020 Sep; 124(38):8201-8208. PubMed ID: 32790379
[TBL] [Abstract][Full Text] [Related]
32. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.
Romeo A; Iacovelli F; Falconi M
Virus Res; 2020 Sep; 286():198068. PubMed ID: 32565126
[TBL] [Abstract][Full Text] [Related]
33. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
Yao TT; Qian JD; Zhu WY; Wang Y; Wang GQ
J Med Virol; 2020 Jun; 92(6):556-563. PubMed ID: 32104907
[TBL] [Abstract][Full Text] [Related]
34. Hot spot profiles of SARS-CoV-2 and human ACE2 receptor protein protein interaction obtained by density functional tight binding fragment molecular orbital method.
Lim H; Baek A; Kim J; Kim MS; Liu J; Nam KY; Yoon J; No KT
Sci Rep; 2020 Oct; 10(1):16862. PubMed ID: 33033344
[TBL] [Abstract][Full Text] [Related]
35. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
Nisole S; Saulnier A; Gatignol A
Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
[No Abstract] [Full Text] [Related]
36. The Potential of Algal Biotechnology to Produce Antiviral Compounds and Biopharmaceuticals.
Rosales-Mendoza S; García-Silva I; González-Ortega O; Sandoval-Vargas JM; Malla A; Vimolmangkang S
Molecules; 2020 Sep; 25(18):. PubMed ID: 32899754
[TBL] [Abstract][Full Text] [Related]
37. Potential of Flavonoid-Inspired Phytomedicines against COVID-19.
Ngwa W; Kumar R; Thompson D; Lyerly W; Moore R; Reid TE; Lowe H; Toyang N
Molecules; 2020 Jun; 25(11):. PubMed ID: 32545268
[TBL] [Abstract][Full Text] [Related]
38. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
Esler M; Esler D
J Hypertens; 2020 May; 38(5):781-782. PubMed ID: 32195824
[No Abstract] [Full Text] [Related]
39. N-acetylcysteine as a potential treatment for COVID-19.
Jorge-Aarón RM; Rosa-Ester MP
Future Microbiol; 2020 Jul; 15():959-962. PubMed ID: 32662664
[No Abstract] [Full Text] [Related]
40. Insights from nanomedicine into chloroquine efficacy against COVID-19.
Hu TY; Frieman M; Wolfram J
Nat Nanotechnol; 2020 Apr; 15(4):247-249. PubMed ID: 32203437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
